nmol/L in summer to 24.5% with concentrations ,50 nmol/L in winter; the corresponding values ranged from 12.5% to 53.1% in nonwhite Canadians. Supplement users had significantly higher 25(OH)D concentrations than did nonusers, and no seasonal differences were found. In nonsupplement users, the prevalence of 25(OH)D concentrations ,50 nmol/L in winter was 37.2% overall and was 60.7% in nonwhites. Conclusions: One-quarter of Canadians did not meet the RDA, but the use of vitamin D supplements contributed to a better 25(OH)D status. Nonwhite Canadians had the highest risk of not achieving DRI recommendations. More than one-third of Canadians not using supplements did not meet the RDA in winter. This suggests that current food choices alone are insufficient to maintain 25(OH)D concentrations of 50 nmol/L in many Canadians, especially in winter.
. However, other factors such as cloud cover, ozone cover, and atmosphere may affect ultraviolet B penetration, and contradictory findings regarding latitude are also evident (8) .
In 2007-2009, Canada reported for the first time national data on vitamin D status using plasma concentrations of 25(OH)D for ages 6-79 y (9) in the Canadian Health Measures Survey (CHMS). The prevalence of meeting commonly used 25(OH)D cutoffs was examined, and ,5% had concentrations ,27.5 nmol/L, '10% had concentrations ,37.5 nmol/L, and 65% had concentrations ,75 nmol/L (9). Seasonal differences in 25(OH)D were modest (9) .
In 2004, Canadians reported ingesting, on average, 208-300 IU vitamin D/d from foods (10)-amounts insufficient to meet the current RDA of 600 to 800 IU (1, 2) . The prevalence of vitamin D supplement users has not been reported at the national level. In older Canadians in British Columbia, 60% reported vitamin D supplement use (11) . In a representative study of Canadians aged 35 y, supplement use .400 IU was associated with the lowest prevalence of 25(OH)D concentrations ,50 nmol/L (5). For older adults to achieve 25(OH)D concentrations .75 nmol/L in Quebec, Canada, supplement intake was necessary (12) .
Concentrations of 25(OH)D in the CHMS showed a significant U-shaped distribution in which children aged 6-11 y and adults aged 60-79 y had higher 25(OH)D concentrations than did adolescents and younger adults (9) . The latter finding was unexpected because older adults had the lowest 25(OH)D concentrations in some studies (13, 14) , in part because of a decreased ability to synthesize vitamin D cutaneously (15) . Vitamin D concentrations differed considerably by racial background, consistent with other Canadian studies (5, 16) . The risk of vitamin D deficiency and inadequacy, however, has not been shown in a sample of Canadian children and adults by race.
This study aimed to determine the prevalence of Canadians meeting the 2011 DRI cutoffs of 30, 40, and 50 nmol/L by season and self-reported ethnic origin in the CHMS-a 2007-2009 national survey with wide age representation. We sought to determine vitamin D supplement use, assess its contribution to achieving DRIs, and examine seasonal differences in 25(OH)D among supplement users and nonusers in Canadians by age, sex, and skin pigmentation.
SUBJECTS AND METHODS

Data and methods
Data for this study are from the 2007-2009 CHMS. The CHMS is the most comprehensive, direct health measures survey ever conducted in Canada. The data in this report were collected over 24 mo in what is now called Cycle 1. Direct physical measures were collected for the household population aged 6-79 y. The survey consisted of 2 parts: 1) an in-home interview to gather information on sociodemographic characteristics, health behaviors, nutrition, and medication and supplement use; and 2) a subsequent visit to a mobile examination center for a series of direct measurements of height and weight, blood pressure, and physical fitness and for collections of urine and blood samples. The blood samples, taken by a certified phlebotomist, were used to measure a variety of substances and metabolites, including plasma 25(OH)D. Respondents unable to visit the mobile examination center were given the option of having the direct measurements taken in their home (17) . Additional information about the CHMS is available in previously published reports (17) (18) (19) (20) .
Sampling plan
The sample used in this analysis consisted of 5306 respondents (2566 males and 2740 females), representing 28.2 million Canadians aged 6-79 y from all regions throughout the 2 y of data collection. Of the households selected to participate in the CHMS, 69.6% agreed. From these respondent households, 88.3% responded to the household questionnaire; of these household respondents, 84.9% reported to the mobile examination center for the direct physical measures. At the national level, the response rate was 51.7%. This overall response rate was not the result of multiplying the household and person response rates, because 2 persons were selected in some households (20) . Residents of Indian reserves, institutions, Crown lands, and certain remote regions as well as full-time members of the Canadian Forces were excluded from the survey. Data were collected over a 2-y period (from March 2007 to February 2009) at 15 sites across the 5 regions of Canada: Atlantic provinces (Newfoundland and Labrador, Prince Edward Island, Nova Scotia, New Brunswick), Quebec, Ontario, the Prairies (Manitoba, Saskatchewan, Alberta; includes Yellowknife), and British Columbia (includes Whitehorse) (18) . Although not every province/territory had a collection site, sites were chosen to represent the Canadian population from east to west, with larger and smaller population densities, and were ordered to take account of seasonality by region and temporal effects (18) . The CHMS sample represents '96% of the Canadian population (28.2 million) aged 6-79 y from all regions living between latitude 43°N and 52°N.
The ages of respondents were grouped according to the CHMS sampling plan: 6-11, 12-19, 20-39, 40-59 , and 60-79 y (18) . Data on age were collected at both the household interview and the mobile examination center visit. For this study, the respondent's age was defined based on the latter. The sample included women who were pregnant or lactating (n = 30), of whom twothirds used a vitamin D supplement. Because of the small sample size, these women were not treated separately in the analyses. Respondents who refused to have their blood drawn, did not have enough blood drawn, or had medical reasons for not having their blood drawn (eg, chemotherapy) were excluded (n = 298). Individuals whose vitamin D measurement was below the lower limit of detection (9.98 nmol/L) were assigned a value half of the lower limit (4.99 nmol/L) (21) . Measured values were compared with cutoffs for 25(OH)D per the Institute of Medicine's recent definitions: ,30 nmol/L indicates deficiency, and 40 and 50 nmol/L are consistent with the EAR and RDA, respectively (1, 2). We also examined the prevalence of plasma 25(OH)D concentrations .150 nmol/L, which is the concentration used to set the Tolerable Upper Intake Level (UL) for vitamin D (1, 2).
25(OH)D analysis
Supplement use
The household questionnaire asked all respondents about their use of medications within the past month, including prescriptions, over-the-counter medications, and health products and herbal remedies. Subjects provided a drug identification number (DIN) for each reported medication, when possible. In addition, respondents reported the last time they had taken that medication, with a range of responses, including today, yesterday, within the past week, within the past month, and .1 mo ago. At the clinic visit, respondents were again asked about their medication and supplement use; those reported at the household visit were verified, and any new ones were recorded. Because 25(OH)D concentrations take '2 mo to equilibrate (22) , this analysis was limited to supplements reported at the household interview and taken within 1 mo of that interview.
To identify DINs associated with vitamin D, the Licensed Natural Health Product Database (LNHPD) and the Drug Product Database (DPD) from Health Canada were consulted. Both active and inactive drugs registered in the DPD as of 3 August 2010 with the active ingredient codes "4924" (vitamin D 2 ), "4922" (vitamin D 3 ), and "703" (vitamin D) were retained (n = 1648). Similarly, all health products and herbal remedies registered in the LNHPD as of 4 August 2010 that contain vitamin D were included (n = 1699), with the exception of topical creams. Items from the DPD and LNHPD were merged and assessed for quality. All dosages reported in IUs were converted to micrograms for consistency. Any item with an ingredient quantity .25 lg was inspected for potential errors and cross verified with its potency value (if provided) or product name. In instances in which the daily dose was a range (eg, 1-2 tablets/d), the lower end was imputed. In the few instances in which quantities could not be determined, these products were assigned a value of 80 IU after examination of the vitamin D content of similar preparations, usually calcium supplements.
Associated factors
Concentrations of 25(OH)D are associated with skin pigmentation, but the CHMS did not collect information on skin pigmentation per se. For this analysis, racial background was used as a proxy. The CHMS asked respondents to choose among an extensive list of backgrounds; those who indicated "white" were categorized as such. Because of the low sample size of nonwhite respondents, the racial background was defined in only 2 categories: white and nonwhite. Seasonality was based on the date respondents visited the mobile examination center, where the blood draw took place -November to March or April to Octoberconsistent with studies based on the National Health and Nutrition Examination Survey (NHANES) in the United States (23) . This categorization represents the "winter" period, during which cutaneous synthesis of vitamin D is unlikely in Canada, and the "summer" period, during which cutaneous synthesis is likely (3, 4) .
Statistical analysis
The unweighted sample sizes of participants with valid plasma 25(OH)D concentrations are shown by sex and age group elsewhere (see Supplementary Table 1 under "Supplemental data" in the online issue). Weighted sample sizes are also provided in this table. Unweighted sample sizes and weighted percentages of subjects by race, sex, and age group are also shown elsewhere (see Supplementary Table 2 under "Supplemental data" in the online issue). Descriptive statistics (frequencies, means) were used to estimate plasma 25(OH)D concentrations by cutoff concentration, supplement use, age group, sex, racial background, and month of blood collection. The analyses were conducted in SUDAAN (version 10 software; Research Triangle Institute, Research Triangle Park, NC). All estimates were based on data weighted to represent the Canadian population aged 6-79 y. Variance estimates (95% CIs) were calculated, and t tests were used to test differences between prevalence and mean estimates. In all analyses, we used the bootstrap weights provided with the data to account for the complex sampling design. Given the 11 df available for variance estimation, denominator df = 11 was specified in each SUDAAN procedure statement. Statistical significance was defined as a P value ,0.05.
RESULTS
To determine the vitamin D status of Canadians, we examined 25(OH)D concentrations relative to the 2011 IOM cutoffs defined for risk of deficiency (,30 nmol/L), for the EAR (40 nmol/L), and for the adequacy of almost everyone (50 nmol/L) year-round and during winter and summer ( Table 1) . Year-round prevalence rates for 25(OH)D concentrations ,30, ,40 and ,50 nmol/L were 5.4%, 12.7%, and 25.7%, respectively. For each cutoff analyzed, some significant differences were found for sex but no significant differences were found between summer and winter. In the determination of those at risk of deficiency (,30 nmol/L), some estimates of prevalence were too low to detect because of the extreme variability or small sample sizes. However, the prevalence of deficiency was as high as 12% in adolescents in winter. To further characterize prevalence below cutoffs, race was included in the analysis ( Table 2) . Nonwhites accounted for '20% of the sample. Canadians who self-reported as white had lower prevalence estimates below all 3 cutoffs for every age and sex group year-round compared with Canadians self-classified as nonwhite. Differences were particularly striking for deficiency estimates (,30 nmol/L), for which the prevalence of nonwhite Canadians was 16.3%. In contrast, the prevalence for white Canadians was ,5% for all age and sex groups. A prevalence ,40 nmol/L was 8.7% for white Canadians year-round. Again, nonwhite Canadians had much higher prevalences: 30.5% (year-round), 33.0% (winter), and 28.3% (summer). Within this group, those aged 12-59 y had higher percentages of concentrations less than the cutoff of ,40 nmol/L than did the youngest and oldest age groups. For nonwhite adolescents, '50% did not have 25(OH)D concentrations .40 nmol/L in winter. Overall, one-fifth of white Canadians had 25(OH)D concentrations ,50 nmol/L; 25% had 25(OH)D concentrations ,50 nmol/L in winter. Nonwhite Canadians again had much higher prevalences (51.4% year-round), with little difference between winter (53.1%) and summer (49.8%).
In 2007-2009, 31% of Canadians aged 6-79 y reported taking at least one supplement containing vitamin D in the previous month. Approximately 95% of all supplements consumed were in the vitamin D 3 form. No difference in supplement use was reported between white (31.9%) and nonwhite (27.3%) Canadians. Among supplement users, 69.3% took 400 IU, which was the dose taken by most children, adolescents, and young adults. Only a small percentage (3.2%) of the total population had VITAMIN D STATUS OF CANADIANS AND SUPPLEMENTS supplement intakes .1000 IU, used mostly by older subjects (40 y), most of whom were female (data not shown). We examined the association between supplement use and 25(OH)D concentrations by season (Table 3) . Overall, in both winter and summer, supplement users had higher 25(OH)D concentrations than did nonusers. This was apparent for almost all age and sex groups in winter. Supplements had less of an effect on 25(OH)D concentrations in summer; only the older age-sex groups clearly showed the effect of higher plasma concentrations with supplement use during this season, ie, those aged 20-39 y (but not males and females, separately), females aged 40-59 y, and men and women aged 60-79 y. Children and teenagers had similar concentrations in summer, whether or not supplements were consumed. Seasonal differences in 25(OH)D concentrations were not apparent among supplement users.
To determine the extent to which some Canadians were not meeting the DRI-consistent cutoffs, prevalences ,30, 40, and 50 nmol/L were examined under various situations known to affect 25(OH)D concentrations ( Table 4) . First, an examination of the relations with and without supplement use showed that nonusers had a prevalence of 6.6%, 15.6%, and 30.4% below the cutoffs, respectively. Some differences between males and females were found. Prevalences below the cutoffs for nonusers were at least twice those for supplement users (2.9%, 6.4%, and 15.4%, respectively; P , 0.05). Because of unstable estimates, we were only able to compare supplement users and nonusers in winter only for the 50 nmol/L cutoff: more than one-third of nonusers had 25(OH)D concentrations ,50 nmol/L, approximately twice that of supplement users (P , 0.05). Finally, an examination of nonwhite Canadians during the winter showed that those not using supplements had the highest prevalence below the 50 nmol/L cutoff. Supplement use (except among males) was associated with a reduced prevalence below cutoffs by 40-50% (P , 0.05). In our initial examination of CHMS data (9), an average seasonal difference of only 6 nmol/L was found between summer and winter. Our current data indicate that the seasonal effect on 25 (OH)D concentrations in Canadians is blunted by supplement use. Furthermore, little or no seasonal effect was observed in nonwhite Canadians, which suggests that sun exposure in summer is not contributing to vitamin D synthesis as much as for white Canadians. Synthesis of vitamin D in darker pigmented skin takes a longer time, and synthesis is dependent on an adequate area of bare skin exposed to ultraviolet B radiation (24) . (25) . Having 1 in 5 nonwhite Canadians at risk of rickets and osteomalacia is a public health concern. Cases of rickets have been described in Canada, despite there being no centralized registry (26) . Recent recommendations on vitamin D intake are mainly based on skeletal effects of vitamin D and risk of rickets and osteomalacia; this study's findings identify nonwhites as a population particularly at risk of deficiency.
In and margarine are mandatory sources (27 Canada recommendation in effect at the time of the study (but since revised) was 800 IU for adults aged .50 y for bone health. Whereas supplements can be effective, it has been shown that individuals with a low income who are probably at need are less likely to use them (28) .
This study had some limitations. The use of vitamin D supplements was determined by a positive response to use within a recent time period. Persons who took vitamin D within the past month were categorized as "users," although there was no information on the frequency or duration of use. Additionally, the dosage on the product was assumed to be the usual dosage taken because quantity was not assessed. Some respondents may have been misclassified or dosages may have been under-or overestimated. Despite this, the large and significant differences in 25(OH)D between those categorized as supplement users and nonusers and their consistency with findings in the literature (5) suggest that the method had reasonable validity. In CHMS Cycle 1, logistical and cost constraints in using mobile examination centers restricted the number of collection sites to 15 (17) (18) (19) (20) . The sample size of various age and sex categories, especially when dividing by season and race, made it difficult to examine more specific subgroups in relation to vitamin D status. As future CHMS cycles become available, exploration of other interrelations might be possible when data from cycles are combined. It was not possible to analyze different races and ethnicities in Canada beyond white and nonwhite. The CHMS did not collect data from Aboriginal peoples living on-reserve who may be at higher risk of vitamin D deficiency.
Comprehensive dietary assessment is not part of the CHMS design; therefore, we could not take into account vitamin D intakes from food. Specific to the analysis of vitamin D status, there were no questions regarding the use of tanning beds or travel to southern destinations, which is common for some Canadians in winter. The overall response rate in the CHMS was 51.7%. Survey weights were adjusted to ensure that the sample was representative of the target population based on certain sociodemographic characteristics. Health status, however, was not accounted for; therefore, it is possible that vitamin D status differed between respondents and nonrespondents.
In conclusion, whereas vitamin D deficiency was low in the population, one-fourth of Canadians had 25(OH)D concentrations that were ,50 nmol/L. In winter (November to March), 3 Significantly different from no supplement use, P , 0.05. 4 Significantly different from males, P , 0.05. We dedicate this manuscript to the memory of our colleague Nick Hidiroglou.
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